Celularity Inc. Class A Common Stock (CELU)
Stock · NASDAQ · Health Care
$1.25as of 10/16/2026
Price chart
Active signals
CELU Signal Track Record
How signals performed across all stocks →What CELU's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 46 | -2.0% | 41% | August 27, 2026 |
| Bollinger Band Breakdown | 23 | -0.8% | 43% | July 31, 2026 |
| Bollinger Band Breakout | 18 | -24.7% | 22% | October 5, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -6.0% | 13% | October 15, 2025 |
| Any 20-session window (baseline) | -6.7% | 35% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CELU
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therap…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 115
- Website
- celularity.com/
Fundamentals
- 1-day range
- $1.57$1.72
- Market cap
- $19.77M
- P/E (trailing)
- —
- P/E (forward)
- -2.96
- EPS (trailing)
- $-3.59
- Dividend yield
- —
- Beta
- 0.88
- Avg. volume
- 3.90M
How Celularity Inc. Class A Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed May 8, 2025 · via SEC EDGAR / Finnhub
Celularity Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- CELUCelularity Inc. Class A Common Stock$1.25▼ 6.02%Market cap $19.77MP/E —$0.5601$2.55
- RKTORocket One Inc. Common Stock$0.507▼ 5.59%Market cap $19.75MP/E —$0.51$2.45
- GRDXGridAI Technologies Corp. Common Stock$4.22▼ 5.38%Market cap $19.91MP/E —$1.87$6.93
- DAREDare Bioscience Inc. Common Stock$0.725▼ 2.03%Market cap $19.92MP/E —$0.69$3.78
- HOWLWerewolf Therapeutics Inc. Common Stock$0.98▼ 1.71%Market cap $19.58MP/E —$0.27$2.24
- CLRBCellectar Biosciences Inc. Common Stock$1.14▼ 4.20%Market cap $20.14MP/E —$1.15$5.07
- NXTCNextCure Inc. Common Stock$6.24▼ 9.30%Market cap $20.19MP/E —$1.55$15.74
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CELU Celularity Inc. Class A Common Stock | $19.77M | — | $1.25 | ▼ 6.02% | $0.5601$2.55 |
| RKTO Rocket One Inc. Common Stock | $19.75M | — | $0.507 | ▼ 5.59% | $0.51$2.45 |
| GRDX GridAI Technologies Corp. Common Stock | $19.91M | — | $4.22 | ▼ 5.38% | $1.87$6.93 |
| DARE Dare Bioscience Inc. Common Stock | $19.92M | — | $0.725 | ▼ 2.03% | $0.69$3.78 |
| HOWL Werewolf Therapeutics Inc. Common Stock | $19.58M | — | $0.98 | ▼ 1.71% | $0.27$2.24 |
| CLRB Cellectar Biosciences Inc. Common Stock | $20.14M | — | $1.14 | ▼ 4.20% | $1.15$5.07 |
| NXTC NextCure Inc. Common Stock | $20.19M | — | $6.24 | ▼ 9.30% | $1.55$15.74 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Philip & Daniele Barach Family Trust · June 19, 2026 · J839.2K
- Philip & Daniele Barach Family Trust · June 19, 2026 · J1.20M
- Barach Philip Alan · June 19, 2026 · J839.2K
- Barach Philip Alan · June 19, 2026 · J1.20M
- Barach Daniele Wolf · June 19, 2026 · J839.2K
- Barach Daniele Wolf · June 19, 2026 · J1.20M
- Brigido Stephen · April 13, 2026 · Option Exercise821
- Brigido Stephen · April 13, 2026 · Tax Withholding268 @ $1.28
- Haines John R · April 13, 2026 · Option Exercise1.6K
- Haines John R · April 13, 2026 · Tax Withholding583 @ $1.28
- Robert J. Hariri · April 13, 2026 · Option Exercise3.3K
- Robert J. Hariri · April 13, 2026 · Tax Withholding1.2K @ $1.28
Institutional Ownership
March 31, 2026
- Total shares held
- 2.09M
- Total value held
- $2.76M
- Institutional holders
- 35
- Unknown764.1K
- Unknown621.1K
- Unknown191.1K
- Unknown127.5K
- Unknown57.8K
- Unknown50.0K
- Unknown44.2K
- Unknown40.4K
- Unknown35.0K
- Unknown29.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Celularity Q1 2027 EPS Up, Announces Partner & Board Member
Celularity posted a first‑quarter 2027 earnings per share of $0.02, up from a loss of $0.84 a year earlier, while sales fell to $3.85 million from $11.43 million. The company will open the Fontaine Vitale facility with its strategic partner and added Naveen Jain to its board. It also closed a $10 million private placement of senior secured convertible notes and warrants, part of a $28 million recapitalization plan.
Celularity Q1 2027 EPS Up, Announces Partner & Board Member. Celularity posted a first‑quarter 2027 earnings per share of $0.02, up from a loss of $0.84 a year earlier, while sales fell to $3.85 million from $11.43 million. The company will open the Fontaine Vitale facility with its strategic partner and added Naveen Jain to its board. It also closed a $10 million private placement of senior secured convertible notes and warrants, part of a $28 million recapitalization plan.